PRIMO 2017

Thursday, February 13, 2020

Hematologic Malignancies
Indolent and aggressive non-Hodgkin Lymphoma including CAR-T cell therapy Julie Vose
Myeloma status, including CAR-T Cell therapy Sagar Lonial
AML and MDS: What’s new and exciting? Brian Jonas
CLL: What’s on the horizon? Susan O’Brien
Gastrointestinal Malignancies
Upper GI malignancies: Role of immunotherapy Rachna Shroff
Lower GI: Colorectal cancer: Therapeutic options & future directions Rachna Shroff

Friday, February 14, 2020

Melanoma, Skin Cancers, RCC
Melanoma and Skin Cancer: Past, present and future Sanjiv Agarwala
RCC: Making sense of the options Donald Trump
GU Cancers
Prostate Cancer: Androgen Disruption-2020 Donald Trump
Bladder Cancer: Where does immunotherapy stand today? Ravi Madan
Debate Frontline Therapy for NSCLC PD1 alone / Combo: PD1 + Chemo Part 1 Luis Raez
Debate Frontline Therapy for NSCLC PD1 alone / Combo: PD1 + Chemo Part 2 Edgardo S. Santos Castillero

Saturday, February 15, 2020

Breast Cancer
De-escalating and escalating neoadjuvant therapy and implications for adjuvant treatment George Sledge
Precision medicine meets breast oncology: Molecular testing to direct treatment decisions William Gradishar
Triple negative breast cancer: new directions in immunotherapy and novel agents Hope S. Rugo
What’s new for HER2+ disease? Shanu Modi
Hormonal management of breast cancer Joyce O’Shaughnessy
Role of genetic markers, risk and therapeutic choices William Gradishar